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Abstract
As the mortality associated with invasive Candida infections remains high, it is important to make optimal use of available diagnostic
tools to initiate antifungal therapy as early as possible and to select the most appropriate antifungal drug. A panel of experts of the
European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
undertook a data review and compiled guidelines for the clinical utility and accuracy of different diagnostic tests and procedures for
detection of Candida infections. Recommendations about the microbiological investigation and detection of candidaemia, invasive candidi-
asis, chronic disseminated candidiasis, and oropharyngeal, oesophageal, and vaginal candidiasis were included. In addition, remarks about
antifungal susceptibility testing and therapeutic drug monitoring were made.
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Introduction
One of the main novelties of the ESCMID Candida Guidelines
is the inclusion of recommendations about diagnostic proce-
dures. The aim of these guidelines is to appraise the different
techniques and procedures for detection and investigation of
Candida infections. Timing of antifungal therapy has been
shown to have major impact on hospital mortality. As the
mortality associated with invasive Candida infections remains
high, it is important to make optimal use of diagnostic tools
to initiate antifungal therapy as early as possible with the
best antifungal drug. In addition to diagnostic tools under-
standing of the local epidemiology, patient risk factors and
resistance proﬁles of Candida species are essential. In some
geographical areas, the number of patients with candidiasis is
rising associated with an increase in the number of patients
with immunosuppression and the expanding utilization of
intensive care units. New diagnostic utilities are being imple-
mented. Most of the new detection methods have been
designed to diagnose invasive candidiasis and have been
shown to be valuable techniques, which could detect infec-
tion early.
This article includes recommendations about conventional
methods of microbiological diagnosis of deep-seated, oropha-
ryngeal, oesophageal and vaginal candidiasis, antifungal sus-
ceptibility testing (AST) and alternative diagnostic procedures
also known as nonculture, biomarker detection procedures.
Some issues about therapeutic drug monitoring (TDM) of
antifungal agents are also commented upon.
Clinicians often use diagnostic tests as a package or strat-
egy based on evidence regarding the accuracy of procedures.
Several proposals have been published for grading quality of
evidence and strength of recommendations for diagnostic
tests and strategies [1]. Although recommendations on diag-
nosis share the fundamental logic of recommendations for
other interventions, they present unique aspects. Conven-
tional diagnostic procedures such as microscopical examina-
tion, culture and identiﬁcation of microorganisms are
essential investigations, and their performance depends on
the possibility of obtaining samples of deep tissues. Conse-
quently, grading the quality of evidence and strength of rec-
ommendation for conventional methods of diagnosing
candidiasis has not been included in this guideline.
However, strengths of recommendations about new non-
culture-based techniques for biomarker detection can be
assigned because many techniques are available showing dif-
ferent levels of accuracy. The use of tests to establish the
presence or absence of the disease and their utility as early
diagnostic methods can be also evaluated. Table 1 shows the
system used in these guidelines for grading quality of evi-
dence about the accuracy of biomarker detection procedures
in the diagnosis of candidiasis.
This document was written by a panel of experts of the
European Fungal Infection Study Group (EFISG) of the ESC-
MID. The text is divided into seven sections, and the object
of the experts was to draw up a series of practical recom-
mendations, with the aim of answering all the questions faced
by health professionals when designing diagnostic strategies
for detecting Candida infections.
1. What are the best tests for diagnosing
candidaemia?
Candidaemia can be deﬁned as the presence of any species
of the genus Candida in the blood. Subsequently, blood cul-
tures (BC) are essential for diagnosing candidaemia [2].
There are a number of international guidelines including gen-
eral recommendations for taking and processing of blood
samples to ensure the optimal isolation of microorganisms
[3–6].
The number of BC recommended in a single session is 3
(2–4), with a total volume varying according to the age of
the patient, 40–60 mL for adults, 2–4 mL for children under
2 kg, 6 mL between 2 and 12 kg, and 20 mL between 12 and
36 kg. The timing for obtaining the BC is one right after the
other from different sites, and venipuncture remains the
technique of choice. A BC set comprises of 60 mL blood for
adults obtained in a single session within a 30-min period
and divided in 10-mL aliquots among three aerobic and three
TABLE 1. System used in these guidelines for grading
quality of evidence about the accuracy of biomarker
detection procedures in the diagnosis of candidiasis (based
on reference 1)
Accuracya
Highly recommended Technique is accurate in >70% of cases (most)
Recommended Technique is accurate in 50–70% of cases
(reasonable number)
Not Recommended Technique is accurate in <50% of cases (small number)
No recommendation No data
Quality of evidence accepted
Level I Evidence from at least one properly designed
prospective multicentre cross-sectional or
cohort study
Level II Evidence from (i) at least one well-designed
prospective single-centre cross-sectional or
cohort study or (ii) a properly designed
retrospective multicentre cross-sectional or
cohort study or (iii) from case-control studies
Level III Opinions of respected authorities, clinical experience,
descriptive case studies or reports of expert
committees
aAccuracy was deﬁned as: (Numbers of true positives + true negatives) divided by
(Numbers of true positives + false positives + false negatives + true negatives).
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anaerobic bottles. The frequency recommended is daily when
candidaemia is suspected, and the incubation period must be
at least 5 days.
When these recommendations have been followed the
sensitivity of BC to detect Candida is 50–75% although lower
sensitivity rates in neutropenic patients and those undergoing
antifungal treatment have been reported [7,8]. Some other
remarks should be noted. Sensitivity varies depending on the
species and system used. For instance, C. glabrata grows less
optimally in the BACTECTM medium (Becton Dickinson
Diagnostic Systems) unless a mycosis bottle is included [7,8].
Identiﬁcation to species level is mandatory because antifungal
therapy can vary according to Candida species. In addition,
yeasts in BC are not always Candida as other emerging and
rare yeast pathogens have been involved in up to 5% of
patients with fungemia. Lysis-centrifugation procedures
showed higher efﬁcacy when older BC systems were used as
comparators. The recommendation of the panel was to use
an automated validated BC system.
The performance of BC is not very high, and they cannot
be considered as early diagnostic techniques. Alternative
procedures based on the detection and quantiﬁcation of fun-
gal biomarkers and metabolites have been developed to
improve and anticipate the detection of candidaemia. Table 2
includes the recommendations of the panel about the clinical
use of these techniques.
The combined detection of mannan and anti-mannan anti-
bodies is considered to be a method for speciﬁc detection of
Candida spp. in serum samples [9]. There is a combination of
tests available [Platelia Candida Antigen Plus (Ag PlusTM) and
Antibody Plus (Ab PlusTM; Bio-Rad Laboratories)]. A number
of studies, based on previous generations of these tests,
reporting evidences from properly designed retrospective
multicentre cross-sectional or cohort study and from case–
control studies have proven their efﬁcacy in the diagnosis of
candidemia, with sensitivity and speciﬁcity rates around 80%
and 85%, respectively, which translates into an accuracy of
50–70%. Serial determinations may be necessary. These
assays can help to detect the infection early because they
can be positive 6 days on average prior blood cultures. It
shows also very high negative predictive value (>85%) and
can be used to rule out infection. The panel considered the
method as recommended for the diagnosis of candidaemia. It
could be used as part of a diagnostic strategy to establish
TABLE 2. Summary of recommendations by Candida disease, specimen and test evaluated
Disease Specimen Test Recommendation Level of evidence
Candidaemia Blood Blood culture Essential investigationa NA
Serum Mannan/anti-mannan Recommended II
B-D-glucan Recommended II
Other antibodies No recommendation No data
Septifast PCR kit No recommendation No data
In-house PCR No recommendation No data
Invasive candidiasis Blood Blood culture Essential investigation NA
Serum Mannan/anti-mannan No recommendation No data
B-D-glucan Recommended II
Septifast PCR kit No recommendation No data
In-house PCR No recommendation No data
Tissue and sterile body ﬂuids Direct microscopy and histopathology Essential investigation NA
Culture Essential investigation NA
Immuno-histochemistry No recommendation No data
Tissue PCR No recommendation No data
In situ hybridization No recommendation No data
Chronic disseminated
candidiasis
Blood Blood culture Essential investigation NA
Serum Mannan/anti-mannan Recommended II
B-D-glucan Recommended II
Septifast PCR kit No recommendation No data
In-house PCR No recommendation No data
Tissue and sterile body ﬂuids Direct microscopy and histopathology Essential investigation NA
Culture Essential investigation NA
Immuno-histochemistry No recommendation No data
Tissue PCR No recommendation No data
In situ hybridization No recommendation No data
Oropharyngeal and
oesophagic candidiasis
Swab Culture Essential investigation NA
In-house PCR No recommendation No data
Biopsyb Direct microscopy and histopathology Essential investigation NA
Culture Essential investigation NA
In-house PCR No recommendation No data
Vaginal candidiasis Swab/vaginal secretions Direct microscopy Essential investigation NA
Culture Essential investigation NA
Commercial tests Use validated test only NA
In-house PCR No recommendation No data
NA, not applicable.
aEssential investigation means it must be done if possible.
bOropharyngeal biopsy is not mandatory.
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the absence of the disease to reduce the unwarranted use of
antifungal agents in prophylactic and empirical regimens in
critical care settings (ICU).
The b-1,3-D-glucan detection (BDG) is also a technique
useful for Candida detection. It is not speciﬁc for Candida
because it is present in many fungal species. The BDG test is
considered to be a panfungal diagnostic method and was
included in the EORTC/MSG (European Organization for
Research and Treatment of Cancer/Mycosis Study Group)
diagnostic criteria for invasive fungal infections in 2008, for
all types of patients. There are several techniques on the
market for the detection of glucan in serum. In Europe and
America, the most used is Fungitell (Associated of Cape
Cod, Inc.). A number of meta-analyses have been undertaken
using data from cross-sectional, cohort and case–control
studies on the diagnosis of candidaemia. The sensitivity of
glucan detection was >65% in most studies with a cut-off
value of 80 pg/mL, with speciﬁcity rates >80%, positive likeli-
hood ratios approximately of 4, negative likelihood ratios of
0.50 and negative predictive values >85%. The use of albu-
min, gauzes, immunoglobulins or haemodialysis was associ-
ated with false positives, and the test seemed of greater
utility in patients who did not have haematological diseases
such as surgical or medical ICU patients suffering from Can-
dida infections [10]. The panel considered the BDG test
(FungitellTM only so far) as recommended for candidemia
detection in adults being also very useful for ruling out infec-
tion. Serial determinations (twice a week) are recommended.
The test has not been validated in children.
Regarding other alternative methods, the panel did not
make any recommendations because no data are available to
evaluate their utility for the clinical diagnosis of candidaemia.
Antibody detection kits such as Serion Elisa Classic and Can-
dida germ tube antibodies are under evaluation, and there are
limited data about their clinical accuracy. Molecular detection
techniques largely PCR-based have also been designed, and
several studies about their reliability are in progress. The
Light Cycler SeptiFast system (Roche) is a PCR-based com-
mercial kit to detect bacteria and fungi in blood samples.
Studies have reported some cases of candidaemia being
detected by this kit, but the number of cases is rather limited
and no recommendation can be made [11–13]. Regarding in-
house PCR techniques, many reports have been published
including more than 1000 patients [14–17]. Their pooled sen-
sitivity and speciﬁcity was calculated over 85% in a meta-anal-
ysis published recently [18]. None of the PCR techniques
included external validation and different material and meth-
ods were used. Third-party appraisal of results and harmoni-
zation of PCR-based techniques should be made before
recommendations can be made regarding clinical utility.
2. What are the best tests for diagnosing
invasive candidiasis?
Invasive candidiasis (IC) can be deﬁned as a deep-seated dis-
ease, frequently a multiorgan infection including candidaemia
although BCs are negative in as many as one-third of the
cases at least in the ICU population [19]. Remarks about BC
were made in the previous section. This section relates the
recommendation by the panel about IC diagnosis using other
specimens and procedures.
Classical diagnostic methods, such as direct microscopy,
histopathology and culture, exhibit a limited sensitivity to
detect IC, and their usefulness depends on the possibility of
obtaining samples of deep tissues which, in many cases, can-
not be taken due to the patient’s condition. Therefore, these
approaches must be considered as essential investigations to
be performed if possible [3,5,6,20].
A number of considerations and recommendations were
highlighted by the panel about the classical methods.
Regarding tissue samples and body ﬂuids from normally
sterile sites, they must be obtained and collected aseptically
and transported to the laboratory promptly. Small samples
are prone to sampling error. Tissue for histopathology
should be placed in ﬁxative as rapidly as possible, and
microscopy should include special stains such as silver
stains and PAS. The use of optical brighteners is recom-
mended for microscopical examination of un-ﬁxed speci-
mens. Microscopic examination requires expertise for
interpretation, and morphology cannot be used for deﬁni-
tive identiﬁcation [21–23].
Samples for culture should not be placed in histopathology
ﬁxatives and must be kept moist. They have to be processed
promptly to avoid multiplication of organisms. If not possible,
storage at 4–5C is recommended. Fungal selective media
must be included, and it should be observed that some spe-
cies take several days (5–14 days) to grow in culture. Yeast
isolation from normally sterile tissues or ﬂuids is usually
indicative of deep-seated infection. Negative culture results
do not exclude Candida infection. Identiﬁcation of the isolate
to species level is mandatory [24,25].
Samples from tissues and body ﬂuids can be also investi-
gated using alternative procedures. Among these, immuno-
histochemistry [21–23], in situ hybridization [26] and analysis
of samples by PCR-based procedures [15,27] have been posi-
tively evaluated in some studies, but they are not generally
available and third-party evaluation of their accuracy has not
been carried out so far. However, some general comments
can be made. PCR-based procedures must use free DNA
materials, and their performance may improve if they are
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carried out following laser microdissection [28]. Immunohis-
tochemistry has shown clinical utility to conﬁrm infection
when yeasts have been seen in tissue and BCs were negative.
The panel recommended genus-speciﬁc antibody commer-
cially available only (e.g. Rabbit anti C. albicans, type A:Bio-
tin, Serotec, No. 1750-5557). It should be noted that only
positive results are reliable and negative results do not
exclude the disease. Regarding in situ hybridization and tissue
and body ﬂuid PCR, there are no clinically validated commer-
cially available kits to detect fungal infections.
Detection of IC by quantiﬁcation of fungal components in
body ﬂuids other than serum has not been evaluated. However,
there are some reports including cases of IC and quantiﬁcation
of serum biomarkers, but signiﬁcant ﬁndings were reported for
the BDG test only [10]. According to these results, the BDG
test can be recommended for IC detection similar to that recom-
mendation made for candidaemia detection (Table 2).
3. What are the best tests for diagnosing
chronic disseminated candidiasis?
The same recommendations made for BC, tissue and body
ﬂuid samples for the detection of IC (Table 2) can be consid-
ered for diagnosing chronic disseminated candidiasis (CDC).
The panel remarked, however, that a tissue biopsy is highly
advisable because CDC is rarely detected by BC. In addition,
the detection of biomarkers can be useful. As for IC, the
BDG test has shown to be strongly associated with clinical
ﬁndings and the panel considered the test as recommended
for CDC detection [10]. Chronic disseminated candidiasis
can be diagnosed by mannan and anti-mannan quantiﬁcation.
A meta-analysis mentioned previously suggests that the tech-
nique is very useful in CDC cases [9]. The report included
21 cases of CDC and mannan and anti-mannan quantiﬁcation
test exhibited 86% of sensitivity rate. Positive results were
seen 16 days in average prior to cultures.
4. What are the best tests for
oropharyngeal candidiasis and oesophagitis?
The essential specimen for the detection of those diseases is
a swab taken from the lesion. A biopsy is not mandatory
(Table 2), but it might discriminate between infection and col-
onization. Swabs must be inoculated on selective media to
avoid overgrowth by colonizing bacteria. Species identiﬁcation
and susceptibility testing are recommended in recurrent/com-
plicated cases and in patients who have been exposed to az-
oles previously. When a biopsy is obtained, it must be
processed according to recommendations stated in the IC
diagnostic procedures section. PCR-based methods have been
evaluated, but no recommendation can be made as results
have not been validated in a clinical setting [5,29,30].
5. What are the best tests for Candida
vaginitis?
Examination of swabs and vaginal secretions is very valuable
in detecting this infection (Table 2). A swab is less useful for
microscopy than secretions. Vaginal secretions spread
directly onto a microscopy slide, and left to dry is recom-
mended. The observation of pseudohyphae can help to
detect the infection, but ﬁlaments can be observed in patient
without infection. In addition, not all Candida spp. form ﬁla-
ments during infection (e.g. C. glabrata), and microscopy in
such cases will show only yeast cells [31].
Culture of swabs and vaginal secretions are also essential
investigations. Semi-quantitative techniques using fungal selec-
tive agar are recommended. Species identiﬁcation and sus-
ceptibility testing are indicated in recurrent/complicated
cases and in patients with prior azole exposure.
Commercial tests designed to detect vaginal candidiasis
can be also used, but the panel recommended the use of val-
idated tests only [32,33]. PCR-based procedures have not
been validated, and no recommendations can be made [34].
6. When are AST recommended for
patient management and when for
epidemiological reasons?
Recommendations for AST were also made by the panel.
The panel considered that AST must be recommended for
patient management for all Candida strains isolated from
blood and other deep sites. Experts advised that reference
procedures [35–39] or validated commercial techniques
should be used [40–43]. However, it should be noted that
discrepant results may be obtained with commercial tech-
niques (such as EtestTM and Sensititre YeastOneTM) as com-
pared to the reference methods particularly for isolates with
borderline MIC values. Importantly, interpretation of AST
results requires expertise and cautious evaluation. It is essen-
tial to ensure the endpoints generated for each species mir-
rors those of reference methods before reference
breakpoints are adopted for interpretation of results by
commercial techniques. Antifungal susceptibility testing can
be useful particularly in some cases such as strains from
patients exposed to antifungal agents, isolates from patients
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with clinical failure, strains belonging to rare and emerging
species and species that are known to be resistant or less
susceptible to antifungal drugs [44,45].
Regarding superﬁcial isolates, AST can be recommended for
patient management in cases who failed to respond to antifun-
gal agents or relapsing infection. Surveillance cultures from
patients exposed to antifungal agents could be also useful.
For epidemiological reasons, the panel recommended that
all isolates from blood and deep sites should be tested using
a reference method. Periodical epidemiological studies
should be carried out including strains isolated from superﬁ-
cial sites to determine the susceptibility proﬁles and resis-
tance rates for each individual centre [44,45].
Table 3 shows breakpoints to interpret AST results
approved by both the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) and the Clinical Laboratory
Standards Institute (CLSI) [46–53].
7. Is therapeutic drug monitoring indicated
for patient management?
The panel indicated that TDM must be used for patients
treated with 5-ﬂuorocytosine. In addition, TDM is not nor-
mally required for drugs used (ﬂuconazole, echinocandins
and amphotericin B formulations) in the treatment for Can-
dida infections except for patients with extra-corporeal
membrane oxygenation (ECMO) treated with echinocandins
as it can reduce the level of the antifungal being used [54–
57].
Therapeutic drug monitoring is recommended if vorico-
nazole or posaconazole is prescribed, and monitoring is
highly recommended in unsatisfactory response to therapy,
suspicion of toxicity or drug interaction(s), impaired liver or
renal function and also in patients on ECMO [58–60].
TABLE 3. Interpretative breakpoints of antifungal agents approved by EUCAST and CLSI for susceptibility testing of Candida
Antifungal Species
EUCAST CLSI
Susceptible Intermediate Resistant Susceptible S-DD Intermediate Resistant
Amphotericin B C. albicans £1 – >1 NEY NEY NEY NEY
C. glabrata £1 – >1 NEY NEY NEY NEY
C. krusei £1 – >1 NEY NEY NEY NEY
C. parapsilosis £1 – >1 NEY NEY NEY NEY
C. tropicalis £1 – >1 NEY NEY NEY NEY
Itraconazole C. albicans NEY NEY NEY £0.12 0.25–0.50 – ‡1
C. glabrata NEY NEY NEY £0.12 0.25–0.50 – ‡1
C. krusei NEY NEY NEY £0.12 0.25–0.50 – ‡1
C. parapsilosis NEY NEY NEY £0.12 0.25–0.50 – ‡1
C. tropicalis NEY NEY NEY £0.12 0.25–0.50 – ‡1
Fluconazole C. albicans £2 4 >4 £2 4 – ‡8
C. glabrata IE IE IE – £32 – ‡64
C. krusei PT PT PT PT PT PT PT
C. parapsilosis £2 4 >4 £2 4 – ‡8
C. tropicalis £2 4 >4 £2 4 – ‡8
Voriconazole C. albicans £0.125 – >0.125 £0.12 – 0.25–0.50 ‡1
C. glabrata IE IE IE IE IE IE IE
C. krusei IE IE IE £0.50 IE 1 ‡2
C. parapsilosis £0.125 – >0.125 £0.12 – 0.25–0.50 ‡1
C. tropicalis £0.125 – >0.125 £0.12 – 0.25–0.50 ‡1
Posaconazole C. albicans £0.06 – >0.06 NEY NEY NEY NEY
C. glabrata IE IE IE NEY NEY NEY NEY
C. krusei IE IE IE NEY NEY NEY NEY
C. parapsilosis £0.06 – >0.06 NEY NEY NEY NEY
C. tropicalis £0.06 – >0.06 NEY NEY NEY NEY
Caspofungin C. albicans NEY NEY NEY £0.25 – 0.50 ‡1
C. glabrata NEY NEY NEY £0.12 – 0.25 ‡0.50
C. krusei NEY NEY NEY £0.25 – 0.50 ‡1
C. parapsilosis NEY NEY NEY £2 – 4 ‡8
C. tropicalis NEY NEY NEY £0.25 – 0.50 ‡1
Micafungin C. albicans NEY NEY NEY £0.25 – 0.50 ‡1
C. glabrata NEY NEY NEY £0.06 – 0.12 ‡0.25
C. krusei NEY NEY NEY £0.25 – 0.50 ‡1
C. parapsilosis NEY NEY NEY £2 – 4 ‡8
C. tropicalis NEY NEY NEY £0.25 – 0.50 ‡1
Anidulafungin C. albicans £0.03 – >0.03 £0.25 – 0.50 ‡1
C. glabrata £0.06 – >0.06 £0.12 – 0.25 ‡0.50
C. krusei £0.06 – >0.06 £0.25 – 0.50 ‡1
C. parapsilosis PT PT PT £2 – 4 ‡8
C. tropicalis £0.06 – >0.06 £0.25 – 0.50 ‡1
NEY, breakpoints have not been established yet; IE, insufﬁcient evidence to set breakpoints; PT, susceptibility testing not recommended as the species is a poor target for
therapy with the drug; S-DD, susceptible dependant on dose.
Data in mg/L.
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